Can levels of antimullerian hormone predict when patients with breast cancer regain ovarian function?

This paper studied whether levels of antimullerian hormone, follicle stimulating hormone and inhibin B could predict when the ovaries regain function after chemotherapy. 

Chemotherapy is used to treat breast cancer. However, it can cause damage to the ovaries and affect fertility. Thus, it would be useful for patients and doctors to know when the ovaries have regained function after chemotherapy, as this can guide treatment decisions. Antimullerian hormone is a protein that indicates an estimated level of eggs left in the ovaries. Follicle-stimulating hormone is a hormone that is associated with development of eggs. Inhibin B is also a protein that can be used to estimate the amount of eggs left in the ovaries. Some studies have suggested an association between antimullerian hormone and follicle stimulating hormone levels with ovarian function after chemotherapy.

Before the patients received chemotherapy, the levels of antimullerian hormone, follicle stimulating hormone and inhibin B were found. Of 124 patients who received chemotherapy, 109 patients had no menstruation for at least 3 months and were analyzed.  Overall, the average level of antimullerian hormone was 0.7 ng/mL. The average level of follicle-stimulating hormone was 5.3 IU/L. The average level of inhibin B was 45.0 pg/mL.

57% of patients had a return of menstruation after an average of 163 days. A younger age, higher levels of antimullerian hormone levels and lower follicle-stimulating hormone levels were associated with return of ovarian function.

Patients with antimullerian hormone levels greater than 0.7 ng/mL before chemotherapy took a shorter time to regain ovarian function than those whose levels were 0.7 ng/mL or less. Patients with follicle-stimulating hormone levels of 10 IU/L or less were 4.7 times more likely to take a shorter time to regain ovarian function. 

The authors concluded that levels of antimullerian hormone and follicle-stimulating hormone were associated with the regain of ovarian function. 

The authors did not study the association to fertility;  they looked at the return of menstruation as an indicator that the ovaries were functioning, but this does not equate to fertility.